Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups.
about
Myopic choroidal neovascularisation: current concepts and update on clinical managementRoles of NFκB-miR-29s-MMP-2 circuitry in experimental choroidal neovascularization.Indocyanine green angiographic features of myopic subfoveal choroidal neovascularization as a prognostic factor after photodynamic therapy.Meta-analysis of best corrected visual acuity after treatment for myopic choroidal neovascularisation.Recent trends in the management of maculopathy secondary to pathological myopia.Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK.Decreased thickness and integrity of the macular elastic layer of Bruch's membrane correspond to the distribution of lesions associated with age-related macular degeneration.The analysis of lacquer crack in the assessment of myopic choroidal neovascularization.Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularizationPredictive factors for visual outcome to intravitreal bevacizumab in young Chinese patients with myopic choroidal neovascularizationVerteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation.Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up.Visual outcomes for high myopic patients with or without myopic maculopathy: a 10 year follow up study.Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.MicroRNA-195a-3p inhibits angiogenesis by targeting Mmp2 in murine mesenchymal stem cells.Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.Epidemiology, treatment pattern and health care utilization of myopic choroidal neovascularization: a population based study.Choroidal neovascularisation in pathological myopia: an update in managementAflibercept as primary treatment for myopic choroidal neovascularisation: a retrospective study.Factors affecting visual outcome of myopic choroidal neovascularization treated with verteporfin photodynamic therapy.Anti-vascular endothelial growth factor for myopic choroidal neovascularization.Myopic maculopathy: a review.Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age.Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues.Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia-1-year results of a prospective series.Serine racemase deficiency attenuates choroidal neovascularization and reduces nitric oxide and VEGF levels by retinal pigment epithelial cells.Comparison of the efficacy of intravitreal ranibizumab for choroidal neovascularization due to pathological myopia with and without a dome-shaped macula.LONG-TERM OUTCOMES OF RANIBIZUMAB TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION IN EAST-ASIAN PATIENTS FROM THE RADIANCE STUDY.Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia.Long-term outcomes of myopic choroidal neovascularisation treated with combined ranibizumab and dexamethasone characterised by multi-modal imaging.Long-Term Follow-Up of Myopic Choroidal Neovascularization Treated with Ranibizumab
P2860
Q26865884-7F77CD29-2187-48E4-B6CD-B7CB1F8D1C53Q33647292-9B06499F-13A1-48AB-A91A-87B01E80FEC1Q34014880-AFFEAEA2-6997-4C5B-9360-2778A57DF577Q34063100-03A7F90A-8BF6-41C8-AED7-A808DAE3C0DDQ34096895-0722221F-DD75-4C90-9BF5-619A391C03C8Q34410824-0D0DD195-485A-4EC9-BF7E-E82A457E1A58Q35083573-451F94D7-7D10-4955-9BA8-7BF9AC90ADCAQ35226772-9A31503A-18AE-4827-A5A2-2E21E4934F05Q35227248-83B5EE20-8591-4300-B1F7-DF990F14C4CAQ35467637-A3440E15-EA3D-468F-BAE7-89D3CF34EC9AQ35590475-43C66D40-9628-4B11-876A-1FB3FDD9133BQ35592511-DC45D259-C119-44DD-A221-284D3D0371ACQ35761791-155B78A4-35FF-4FCD-B76A-0CFF913B89C6Q35763017-3353A7DF-BA6A-460D-A7AE-7BE5FDA2DB8BQ35962115-55B1D17F-C75F-40E1-A0E9-61F49C711916Q36093311-10D78F04-E2A6-4E25-90E4-9F6B9764B062Q36243561-738E0A05-DF5B-4855-8FE0-0455DA8906A2Q36290241-7299F91B-AC28-4CD0-B573-21CFF85F5D86Q36453318-CAD89F94-A7CF-4158-B362-91285C3CAEC3Q36955728-645936F7-4787-44EE-BF0F-E5634EA239EBQ37929305-B41293CF-E622-45B6-9A7A-9B1395789D8CQ38030764-FC622308-83AE-4C8A-9D28-4A7523EE390CQ41016116-75AF9260-CDF6-4471-9493-93DC084CF835Q42840733-1697233E-C3C6-4A48-A37F-3FD19EB938EDQ45064366-E2EC7543-444F-4D74-8547-387B65710417Q47689628-F535552B-6E42-4F31-9B99-19B0D9E2CE62Q49487410-BFE3DA55-EBB6-4291-920E-39E1A522C7B8Q49930249-7F1B8864-CF2A-4D21-9D04-F105F5996FE7Q51453732-5189BB55-6470-48D9-BA48-B820C5DE5C9AQ53626702-C3C60835-C34D-406B-B826-35A1216E11F0Q57652423-28AFC1AC-181A-4F37-8159-138149223870
P2860
Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Long-term visual prognosis of ...... comparison between age groups.
@en
Long-term visual prognosis of ...... comparison between age groups.
@nl
type
label
Long-term visual prognosis of ...... comparison between age groups.
@en
Long-term visual prognosis of ...... comparison between age groups.
@nl
prefLabel
Long-term visual prognosis of ...... comparison between age groups.
@en
Long-term visual prognosis of ...... comparison between age groups.
@nl
P2093
P1433
P1476
Long-term visual prognosis of ...... comparison between age groups.
@en
P2093
Kenjiro Yasuzumi
Manabu Mochizuki
Soh Futagami
Takashi Tokoro
Takayuki Baba
Takayuki Takashima
Takeshi Yoshida
Yoshiteru Ohtake
P304
P356
10.1016/S0161-6420(01)01007-7
P577
2002-04-01T00:00:00Z